Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. This ratio does not apply to banks.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. This ratio does not apply to banks.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, abrdn Life Sciences Investors's Enterprise Value is $342.39 Mil.
abrdn Life Sciences Investors's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 was $23.52 Mil. Therefore, abrdn Life Sciences Investors's EV-to-Revenue ratio for today is 14.56.
abrdn Life Sciences Investors Enterprise Value Historical Data
The historical data trend for abrdn Life Sciences Investors's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
abrdn Life Sciences Investors Annual Data
Trend
Sep17
Sep18
Sep19
Sep20
Sep21
Sep22
Sep23
Enterprise Value
348.89
419.87
513.10
350.78
334.09
abrdn Life Sciences Investors Semi-Annual Data
Sep17
Mar18
Sep18
Mar19
Sep19
Mar20
Sep20
Mar21
Sep21
Mar22
Sep22
Mar23
Sep23
Enterprise Value
513.10
415.59
350.78
365.13
334.09
Competitive Comparison
For the Asset Management subindustry, abrdn Life Sciences Investors's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
abrdn Life Sciences Investors Enterprise Value Distribution
For the Asset Management industry and Financial Services sector, abrdn Life Sciences Investors's Enterprise Value distribution charts can be found below:
* The bar in red indicates where abrdn Life Sciences Investors's Enterprise Value falls into.
abrdn Life Sciences Investors Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
abrdn Life Sciences Investors's Enterprise Value for the fiscal year that ended in Sep. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
abrdn Life Sciences Investors (NYSE:HQL) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
abrdn Life Sciences Investors's current Enterprise Value is $342.39 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. abrdn Life Sciences Investors's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 was $23.52 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
abrdn Life Sciences Investors Enterprise Value Related Terms
Thank you for viewing the detailed overview of abrdn Life Sciences Investors's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
abrdn Life Sciences Investors (abrdn Life Sciences Investors) Business Description
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing primarily in securities of Life Sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser, abrdn Inc to have significant potential for above-average growth.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HQL has been successfully added to your 